Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Focusrite warns on FY profits amid 'challenging market conditions'

(Sharecast News) - Audio products business Focusrite warned on Monday that full-year revenue and profits would be lower than consensus estimates as a result of "challenging market conditions" and continued weakness in Asia. Focusrite said revenues for the year ending 31 August were now anticipated to be no less than £155.0m, while underlying earnings were pegged to be in the range of £27.0m to £30.0m, with a heavier weighting towards H2 than in FY23. Consensus estimates for sales sat at £182.0m, while forecasts for EBITDA were £38.0m.

The AIM-listed group said its first-half performance was impacted by "similar factors across the group's geographic regions", noting that the global content creation market "continues to struggle" due to a number of macroeconomic issues. Content creation revenue in Asia showed "particular continued weakness", with now 18 months of continuous decline, the largest negative impacts being in China and Japan, and no improvement likely to take place in the remainder of the year.

However, notwithstanding the firm's "cautious outlook" for the current financial year, Focusrite said it remains "well-positioned for future growth", when market conditions in the content creation market improve, with a clear focus on increasing market share, and delivering new products as well as making targeted acquisitions.

As of 1300 GMT, Focusrite shares were down 27.34% at 279.75p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.
McCarthy out, Adshead in as Ultimate Products chair
(Sharecast News) - Ultimate Products, the parent of homeware brands including Salter and Beldray, announced a change in its leadership on Monday, with James 'Jim' McCarthy deciding to step down as non-executive chair from 31 July.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.